Ann: MSB Expands JCR Partnership To Brain Disease In Newborns, page-28

This is good news. I was half expecting some news re. our cells and newborn infants but I thought it might be necrotising entercolitis. NEC is imo an obvious application for cells that can heal the gut. There doesn't seem much available to treat either of these devastating conditions. I think doctors could make a good case for reimbursement for off label use because of very high cost of intensive care and both can result in cognitive impairment.

My layperson's view of this ann (and also EB one) is not just that the importance of the applications themselves but the subtext that JCR sees potential application for our cells for the incredibly hard basket. Imo it's then reasonable to think our cells could have application for the too hard basket of conditions where there are existing therapies.

I note this is the first mention of our Crohn's Disease candidate. I've been banging on about this on this forum for at least a couple of years. I don't know why it hasn't been mentioned because the similarity between IBD and GI-GvHD is well known among IBD specialists. I think it's common sense anyway: Gut, liver, skin - that pretty much covers IBD.

Surgeons are cautious about operating on active Crohn's Disease. It can go crazy. Teenage girls present a particular challenge when the disease is driven by hormones. Doctors will throw everything at it to try to avoid surgery.

IBD is a large and growing market. I've already posted refs to support my view that it's not under control. Children are being diagnosed at an increasingly young age, particularly in Canada. Younger age is associated with more aggressive disease. I already proved refs for the significant surgery rates in children despite the anti TNF drugs. IBD can also result in liver transplant. Assuming approval, I think gastroenterologists in acute medicine will be keen to get their hands on Remestemcel-L.

Professor Kurtzberg said the cells don't suppress the immune system. Suppressing the immune system is the mainstay in current IBD treatment. The problem with that approach is the recent change in thinking. Paul Moayeddi is highly regarded in the IBD community and imo it's worth re-posting his comment taken from an interview published in a medical journal that I quoted in an earlier post:

"In the past, inflammatory bowel disease (IBD) was thought to be an autoimmune disease, but the current thinking is that it is actually an immune disease mediated by an antigen, presumably a microbial antigen to which the immune system is reacting."

Paul Moayeddi says the clinical trials in FMT provide 'reasonably convincing' evidence of the microbiome's importance in ulcerative colitis (the more common form of IBD) This is likely also the case in Crohn's Disease. What PM says imo supports what proponents of dietary therapy have been saying for two decades; it likely applies to all autoimmune diseases. You can see the recent interest in the microbiome in juvenile ideopathic arthritis, for example, and other autoimmune diseases.

I think there was initially so much opposition to FMT because it calls current practice in IBD into question. Also, it's difficult to address the microbiome without first healing the gut. Bacteria won't adhere to inflammation. I would go further, as I've previously said, and say the key is to restore the epithelial barrier. Recent ann on EB and research on MSCs and NEC make me think our cells have ability to do this.

I think our cells are the way to go for all autoimmune diseases for three crucial reasons, the lack of side effects being the third.

.


ALL IMO. GLTAH

.






.